NASDAQ:MBRX

Moleculin Biotech - MBRX News Today

$0.94

+0.04 (+4.44%)

(As of 03/30/2023 12:00 AM ET)

Add

Compare

Today's Range: $0.89
▼
$0.95
50-Day Range: $0.90
▼
$1.30
52-Week Range: $0.82
▼
$2.05

Volume: 73,235 shs
Average Volume: 67,122 shs
Market Capitalization: $26.91 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.50

Institutional Ownership

Get Moleculin Biotech News Delivered to You Automatically

MBRX Media Mentions By Week

MBRX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

MBRX
News Sentiment
▼
0.54

0.60
▲
Average
Medical
News Sentiment

MBRX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

MBRX Articles
This Week
▼
8

1
▲
MBRX Articles
Average Week

Source

Source	Headline
	Moleculin Biotech (NASDAQ:MBRX) Now Covered by StockNews.com americanbankingnews.com - March 28 at 1:30 AM
	Moleculin Biotech, Inc. (MBRX) Upgraded to Buy: What Does It Mean for the Stock? finance.yahoo.com - March 27 at 2:17 PM
	Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2022 Earnings Call Transcript finance.yahoo.com - March 27 at 9:16 AM
	Moleculin Biotech (NASDAQ:MBRX) Receives "Outperform" Rating from Oppenheimer americanbankingnews.com - March 25 at 6:22 AM
	Maxim Group Sticks to Its Buy Rating for Moleculin Biotech (MBRX) markets.businessinsider.com - March 24 at 7:27 PM
	Q4 2022 Moleculin Biotech Inc Earnings Call finance.yahoo.com - March 24 at 8:27 AM
	Moleculin Biotech, Inc.: Moleculin Reports Full Year 2022 Financial Results and Provides Pipeline Update finanznachrichten.de - March 23 at 10:00 AM
	Moleculin Reports Full Year 2022 Financial Results and Provides Pipeline Update finance.yahoo.com - March 23 at 10:00 AM
	Moleculin Announces Interim Phase 2 Data in STS Clinical Trial and Update on Recruiting, Preliminary Efficacy and Expected Milestones for AML Clinical Trials finance.yahoo.com - March 22 at 5:10 PM
	Earnings Outlook For Moleculin Biotech msn.com - March 21 at 4:01 PM
	Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 finance.yahoo.com - March 21 at 4:01 PM
	San Francisco Biotech News bizjournals.com - March 15 at 9:29 PM
	Moleculin to Report Full Year 2022 Financial Results on March 22, 2023 and Host Conference Call and Webcast finance.yahoo.com - March 15 at 11:28 AM
	In wake of Silicon Valley Bank's implosion, companies urged to change how they bank bizjournals.com - March 14 at 6:48 PM
	Moleculin to Present at the Oppenheimer 33rd Annual Healthcare Conference finance.yahoo.com - March 13 at 9:36 AM
	Moleculin Announces Publication of Data Supporting Development of Non-Cardiotoxic Anthracycline for the Treatment of Cancer in Peer-Reviewed European Journal of Cancer finance.yahoo.com - March 9 at 10:43 AM
	Moleculin Biotech, Inc. (MBRX) uk.finance.yahoo.com - March 4 at 4:02 AM
	Moleculin Announces Dosing of First Subject in Italy for Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML) finance.yahoo.com - March 1 at 1:02 PM
	MBRX Moleculin Biotech, Inc. seekingalpha.com - February 16 at 12:01 AM
	Moleculin Reveals Final Topline Data From European Study Of Annamycin In Leukemia Setting finance.yahoo.com - February 13 at 2:50 PM
	Moleculin Biotech Reports Topline Data From European Phase 1 Trial Of Annamycin markets.businessinsider.com - February 13 at 9:41 AM
	Moleculin Announces Final Topline Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML) finance.yahoo.com - February 13 at 9:41 AM
	Analysts Conflicted on These Healthcare Names: Achilles Therapeutics (ACHL), Cidara Therapeutics (CDTX) and Moleculin Biotech (MBRX) markets.businessinsider.com - January 15 at 8:05 AM
	Moleculin to Present at the Virtual Investor 2023 Companies to Watch Event finance.yahoo.com - January 5 at 1:10 PM
	Moleculin Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML) finance.yahoo.com - December 21 at 8:56 AM
	Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Invest In Growth? finance.yahoo.com - December 19 at 12:24 PM
	Maxim Group Keeps Their Buy Rating on Moleculin Biotech (MBRX) markets.businessinsider.com - December 17 at 12:47 PM
	Moleculin Biotech's Annamycin In Leukemia Study Shows 80% Overall Response Rate finance.yahoo.com - December 15 at 6:31 PM
	Moleculin Reports 80% Overall Response Rate in Final Cohort of Phase 1 Single Agent Trial of Annamycin for the Treatment of Acute Myeloid Leukemia (AML) finance.yahoo.com - December 15 at 1:30 PM
	Moleculin Gets FDA Fast-Track Designation for WP1122 in Glioblastoma Multiforme >MBRX marketwatch.com - December 7 at 6:17 PM
	Moleculin Announces FDA Fast Track Designation For WP1122 markets.businessinsider.com - December 7 at 6:17 PM
	Biotech firm Moleculin touts strong cash position, clinical trials in Q3 earnings call finance.yahoo.com - November 15 at 10:41 AM
	Moleculin Reports Third Quarter 2022 Financial Results and Provides Pipeline Update finance.yahoo.com - November 10 at 7:23 PM
	How to Invest in Biotechnology thestreet.com - November 7 at 11:44 AM
	Moleculin to Report Third Quarter 2022 Financial Results on November 10, 2022 and Host Inaugural Quarterly Conference Call and Webcast finance.yahoo.com - November 7 at 11:44 AM
	Moleculin Provides Update on Second Multiple Ascending Dose (MAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK finance.yahoo.com - October 14 at 8:53 AM
	Moleculin Biotech's Potential Antiviral Compound Selected For NIAID-Funded Animal Studies msn.com - September 27 at 3:27 PM
	Moleculin Biotech WP1122 Portfolio Compound, WP1096, Selected for NIAID-Funded Animal Studies as Novel Potential Antiviral finance.yahoo.com - September 27 at 10:27 AM
	Moleculin Biotech to Present at the Virtual Investor Innovations in Acute Myeloid Leukemia (AML) Spotlight Event finance.yahoo.com - September 23 at 2:05 PM
	Moleculin Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care finance.yahoo.com - September 8 at 4:17 PM
	Moleculin to Present at the H.C. Wainwright 24th Annual Global Investment Conference finance.yahoo.com - September 7 at 12:18 PM
	Moleculin Biotech Announces Receipt Of Orphan Drug Designation For WP1122 - Quick Facts nasdaq.com - September 6 at 9:51 AM
	Moleculin Announces Completion of Third Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK finance.yahoo.com - August 19 at 9:39 AM
	Moleculin Biotech GAAP EPS of -$0.24 seekingalpha.com - August 16 at 7:21 PM
	Moleculin Reports Second Quarter 2022 Financial Results and Provides Programs Update finance.yahoo.com - August 15 at 12:08 PM
	Moleculin Announces Completion of First Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK finance.yahoo.com - June 16 at 8:46 AM
	Moleculin begins human trial of WP1122 to treat COVID-19 seekingalpha.com - May 26 at 6:49 PM
	Moleculin Biotech Doses Healthy Volunteers For Covid-19 In Early-Stage Study Of WP1122 msn.com - May 26 at 6:49 PM
	Moleculin Commences Dosing in Healthy Volunteers in Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19 finance.yahoo.com - May 26 at 9:22 AM
	Moleculin to Present at the H.C. Wainwright Global Investment Conference finance.yahoo.com - May 19 at 9:13 AM

Get Moleculin Biotech News Delivered to You Automatically

This page (NASDAQ:MBRX) was last updated on 3/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Moleculin Biotech - MBRX News Today

MBRX Media Mentions By Week

MBRX Media Sentiment

MBRX News Coverage

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info